Title
Category
Credits
Event date
Cost
The Role of JAK Inhibitors in the Management of Myelofibrosis
  • Myeloproliferative Neoplasms
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
Allogeneic hematopoietic cell transplant is the only potentially curative treatment option resulting in long-term remissions for patients with myelofibrosis (MF), but it is associated with a significant rate of transplant-related complications and morbidity in patients with lower-risk MF. Patients have a significant symptom burden and a propensity for disease transformation to accelerated and blast phases. For many years, ruxolitinib was the only FDA-approved drug for the treatment of intermediate-risk or high-risk MF. Since then, multiple new JAK inhibitors have been approved by the FDA.